Healthcare - Biotechnology - NASDAQ - US
$ 5.84
-5.96 %
$ 222 M
Market Cap
-3.74
P/E
CASH FLOW STATEMENT
-46.1 M
OPERATING CASH FLOW
10.7 M
INVESTING CASH FLOW
46.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Orchestra BioMed Holdings, Inc.
| Net Income | -49.1 M |
| Depreciation & Amortization | 287 K |
| Capital Expenditures | -78 K |
| Stock-Based Compensation | 7.62 M |
| Change in Working Capital | -3.31 M |
| Others | -5.19 M |
| Free Cash Flow | -46.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (49.1) | (33.6) | (23.0) | (21.4) |
| Depreciation & Amortization | 0.3 | 0.2 | 0.2 | 0.1 |
| Deferred Income Tax | 0 | (3.6) | 0.3 | 0 |
| Stock Based Compensation | 7.6 | 3.4 | 0.3 | 0.2 |
| Other Operating Activities | (1.6) | 4.8 | 0.2 | 2.9 |
| Change in Working Capital | (3.3) | (0.5) | 2.6 | (8.1) |
| Cash From Operations | (46.1) | (29.3) | (19.4) | (26.2) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 78 K | (0.6) | (0.3) | (0.5) |
| Other Items | 10.8 | (63.5) | 13.3 | 27.5 |
| Cash From Investing Activities | 10.7 | (64.1) | 13.0 | 27.0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (10.8) | 3.6 | (4.0) | 10.0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 57.1 | (10.1) | 7 K | 0 |
| Cash From Financing Activities | 46.2 | 103.3 | (4.0) | 10.0 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 10.8 | 18.0 | (10.4) | 10.8 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (46.2) | (29.9) | (19.7) | (26.7) |